Physician profile
David Smart
NPI 1295027449
$5,319.74
in general payments reported to CMS, 2019-2025
23 companies · $2,850 in 2025
The $2,850 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.30 · 2020: $197 · 2021: $296 · 2022: $557 · 2023: $585 · 2024: $781 · 2025: $2,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $2,053.56 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Galderma Laboratories, L.P. | $715.82 | 2019-2025 | Dysport, Nemluvio, Aklief |
| Abbvie INC. | $581.03 | 2020-2025 | Skyrizi, Rinvoq |
| Revance Therapeutics, INC. | $345.23 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $242.13 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $234.00 | 2022-2024 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $220.92 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $218.23 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $160.32 | 2020-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $105.88 | 2020-2025 | |
| Amgen INC. | $85.14 | 2022-2023 | Otezla |
| Allergan, INC. | $68.06 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.34 | 2019-2023 | Jublia |
| Leo Pharma INC. | $60.71 | 2024-2025 | Adbry |
| Incyte Corporation | $33.11 | 2021-2025 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29.74 | 2020 | |
| Dermira, INC. | $22.12 | 2020 | |
| Biofrontera INC. | $20.90 | 2025 | Ameluz |
| Botanix Sb INC | $16.70 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $14.21 | 2024 | Sotyktu |
| Solta Medical, A Division of Bausch Health US, LLC | $13.18 | 2020 | |
| Merz North America, INC. | $11.56 | 2019 | |
| Organon LLC | $1.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.